

Global Hereditary Angioedema Therapeutic Market Size study & Forecast, by Drug Class (C1-esterase inhibitor, Bradykinin B2 receptor antagonist, Kallikrein inhibitor, Others), By Treatment Type (Prophylaxis, On-demand), By Route of Administration (Intravenous, Subcutaneous, Oral) and Regional Analysis, 2023-2030

<https://marketpublishers.com/r/G20FA72AEEC2EN.html>

Date: July 2023

Pages: 200

Price: US\$ 4,950.00 (Single User License)

ID: G20FA72AEEC2EN

Abstracts

Global Hereditary Angioedema Therapeutic Market is valued at approximately USD 4.42 billion in 2022 and is anticipated to grow with a healthy growth rate of more than 8.5% over the forecast period 2023-2030. Hereditary angioedema is a rare genetic disorder that causes recurrent episodes of swelling in various parts of the body, including the face, throat, limbs, and abdomen. These attacks can be severe and life-threatening if they involve the airway. The Hereditary Angioedema Therapeutic market is expanding because of factors such as rising prevalence of genetic disorders and increasing adoption of novel therapeutics. Androgens are hormones that can increase the production of C1 inhibitors and reduce the frequency and severity of HAE attacks. However, they have significant side effects, including masculinization in women and children, liver toxicity, and an increased risk of blood clots. Its prevalence has progressively increased during the last few decades.

According to the World Health Organization, Genetic disorders and congenital abnormalities occur in about 2%-5% of all live births, accounting for up to 30% of pediatric hospital admissions, and cause about 50% of childhood deaths in industrialized countries. Furthermore, as per Statista, in 2020 Europe conducted a survey and found that 36% of respondents in the United Kingdom were unaware of the significance heredity plays in a person's proclivity to hereditary disorders. Another

important component driving space is increasing adoption of novel therapeutics. According to Statista, the top therapy areas worldwide is projected to spend on is about USD 377 billion on oncology followed by immunology is projected to be second with around USD 177 billion of spending. In addition, in 2022, Wave Life Sciences Ltd had a strategic collaboration to advance oligonucleotide therapeutics, including Wave's preclinical RNA editing program. The initial research duration for the discovery collaboration is four years. GSK's unique human genetic insights, as well as its global development and commercial capabilities, are combined with Wave's patented discovery and medication development platform, PRISMTM. Also, advancements in formulation and technological advancement in drugs related to angioedema would create a lucrative growth prospectus for the market over the forecast period. However, lack of awareness about hereditary angioedema therapeutics stifles market growth throughout the forecast period of 2023-2030.

The key regions considered for the Global Hereditary Angioedema Therapeutic Market study include Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 owing to the presence of key market players in the region. According to Statista, North America dominated the worldwide cell and gene therapy industry in 2020, accounting for about 56% of the total market and expected to increase at a rate of 33.8% between 2021 and 2027. Asia Pacific is expected to grow significantly during the forecast period, owing to factors such as rising geriatric and target populations, and active participation of government and nonprofit organizations in the market space.

Major market players included in this report are:

CSL Limited

Takeda Pharmaceutical Company Limited

Pharming Healthcare Inc

Sanofi S.A.

BioCryst Pharmaceuticals Inc

Ionis Pharmaceuticals, Inc

Shire Plc

Attune Pharmaceuticals, Inc

Adverum Biotechnologies, Inc

KalVista Pharmaceuticals, Inc

Recent Developments in the Market:

In March 2023, Sanofi SA intended to pay \$2.9 billion for Provention Bio Inc in order to boost its therapeutic pipeline. Sanofi would get complete ownership of Tzield, a

medicine that was authorized in the United States for delaying the onset of type 1 diabetes's third and final stage.

Global Hereditary Angioedema Therapeutic Market Report Scope:

Historical Data – 2020 - 2021

Base Year for Estimation – 2022

Forecast period - 2023-2030

Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends

Segments Covered - Drug Class, Treatment Type, Route of Administration, Region

Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa

Customization Scope - Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Drug Class

C1-esterase inhibitor

Bradykinin B2 receptor antagonist

Kallikrein inhibitor

Others

By Treatment Type

Prophylaxis

On-demand

By Route of Administration

Intravenous

Subcutaneous

Oral

By Region:

North America

U.S.

Canada

Europe

UK

Germany

France

Spain

Italy

ROE

Asia Pacific

China

India

Japan

Australia

South Korea

RoAPAC

Latin America

Brazil

Mexico

Middle East & Africa

Saudi Arabia

South Africa

Rest of Middle East & Africa

Contents

CHAPTER 1. EXECUTIVE SUMMARY

- 1.1. Market Snapshot
- 1.2. Global & Segmental Market Estimates & Forecasts, 2020-2030 (USD Billion)
 - 1.2.1. Hereditary Angioedema Therapeutic Market, by Region, 2020-2030 (USD Billion)
 - 1.2.2. Hereditary Angioedema Therapeutic Market, by Drug Class, 2020-2030 (USD Billion)
 - 1.2.3. Hereditary Angioedema Therapeutic Market, by Treatment Type, 2020-2030 (USD Billion)
 - 1.2.4. Hereditary Angioedema Therapeutic Market, by Route of Administration, 2020-2030 (USD Billion)
- 1.3. Key Trends
- 1.4. Estimation Methodology
- 1.5. Research Assumption

CHAPTER 2. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTIC MARKET DEFINITION AND SCOPE

- 2.1. Objective of the Study
- 2.2. Market Definition & Scope
 - 2.2.1. Industry Evolution
 - 2.2.2. Scope of the Study
- 2.3. Years Considered for the Study
- 2.4. Currency Conversion Rates

CHAPTER 3. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTIC MARKET DYNAMICS

- 3.1. Hereditary Angioedema Therapeutic Market Impact Analysis (2020-2030)
 - 3.1.1. Market Drivers
 - 3.1.1.1. Rising prevalence of genetic disorders
 - 3.1.1.2. Increasing adoption of novel therapeutics
 - 3.1.2. Market Challenges
 - 3.1.2.1. Lack of awareness about Hereditary Angioedema Therapeutic
 - 3.1.3. Market Opportunities
 - 3.1.3.1. Advancements in Formulation

3.1.3.2. Technological advancement in drugs related to Angioedema

CHAPTER 4. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTIC MARKET INDUSTRY ANALYSIS

- 4.1. Porter's 5 Force Model
 - 4.1.1. Bargaining Power of Suppliers
 - 4.1.2. Bargaining Power of Buyers
 - 4.1.3. Threat of New Entrants
 - 4.1.4. Threat of Substitutes
 - 4.1.5. Competitive Rivalry
- 4.2. Porter's 5 Force Impact Analysis
- 4.3. PEST Analysis
 - 4.3.1. Political
 - 4.3.2. Economical
 - 4.3.3. Social
 - 4.3.4. Technological
 - 4.3.5. Environmental
 - 4.3.6. Legal
- 4.4. Top investment opportunity
- 4.5. Top winning strategies
- 4.6. COVID-19 Impact Analysis
- 4.7. Disruptive Trends
- 4.8. Industry Expert Perspective
- 4.9. Analyst Recommendation & Conclusion

CHAPTER 5. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTIC MARKET, BY DRUG CLASS

- 5.1. Market Snapshot
- 5.2. Global Hereditary Angioedema Therapeutic Market by Drug Class, Performance - Potential Analysis
- 5.3. Global Hereditary Angioedema Therapeutic Market Estimates & Forecasts by Drug Class 2020-2030 (USD Billion)
- 5.4. Hereditary Angioedema Therapeutic Market, Sub Segment Analysis
 - 5.4.1. C1-esterase inhibitor
 - 5.4.2. Bradykinin B2 receptor antagonist
 - 5.4.3. Kallikrein inhibitor
 - 5.4.4. Others

CHAPTER 6. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTIC MARKET, BY TREATMENT TYPE

- 6.1. Market Snapshot
- 6.2. Global Hereditary Angioedema Therapeutic Market by Treatment Type, Performance - Potential Analysis
- 6.3. Global Hereditary Angioedema Therapeutic Market Estimates & Forecasts by Treatment Type 2020-2030 (USD Billion)
- 6.4. Hereditary Angioedema Therapeutic Market, Sub Segment Analysis
 - 6.4.1. Prophylaxis
 - 6.4.2. On-demand

CHAPTER 7. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTIC MARKET, BY ROUTE OF ADMINISTRATION

- 7.1. Market Snapshot
- 7.2. Global Hereditary Angioedema Therapeutic Market by Route of Administration, Performance - Potential Analysis
- 7.3. Global Hereditary Angioedema Therapeutic Market Estimates & Forecasts by Route of Administration 2020-2030 (USD Billion)
- 7.4. Hereditary Angioedema Therapeutic Market, Sub Segment Analysis
 - 7.4.1. Intravenous
 - 7.4.2. Subcutaneous
 - 7.4.3. Oral

CHAPTER 8. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTIC MARKET, REGIONAL ANALYSIS

- 8.1. Top Leading Countries
- 8.2. Top Emerging Countries
- 8.3. Hereditary Angioedema Therapeutic Market, Regional Market Snapshot
- 8.4. North America Hereditary Angioedema Therapeutic Market
 - 8.4.1. U.S. Hereditary Angioedema Therapeutic Market
 - 8.4.1.1. Drug Class breakdown estimates & forecasts, 2020-2030
 - 8.4.1.2. Treatment Type breakdown estimates & forecasts, 2020-2030
 - 8.4.1.3. Route of Administration breakdown estimates & forecasts, 2020-2030
 - 8.4.2. Canada Hereditary Angioedema Therapeutic Market
- 8.5. Europe Hereditary Angioedema Therapeutic Market Snapshot

- 8.5.1. U.K. Hereditary Angioedema Therapeutic Market
- 8.5.2. Germany Hereditary Angioedema Therapeutic Market
- 8.5.3. France Hereditary Angioedema Therapeutic Market
- 8.5.4. Spain Hereditary Angioedema Therapeutic Market
- 8.5.5. Italy Hereditary Angioedema Therapeutic Market
- 8.5.6. Rest of Europe Hereditary Angioedema Therapeutic Market
- 8.6. Asia-Pacific Hereditary Angioedema Therapeutic Market Snapshot
 - 8.6.1. China Hereditary Angioedema Therapeutic Market
 - 8.6.2. India Hereditary Angioedema Therapeutic Market
 - 8.6.3. Japan Hereditary Angioedema Therapeutic Market
 - 8.6.4. Australia Hereditary Angioedema Therapeutic Market
 - 8.6.5. South Korea Hereditary Angioedema Therapeutic Market
 - 8.6.6. Rest of Asia Pacific Hereditary Angioedema Therapeutic Market
- 8.7. Latin America Hereditary Angioedema Therapeutic Market Snapshot
 - 8.7.1. Brazil Hereditary Angioedema Therapeutic Market
 - 8.7.2. Mexico Hereditary Angioedema Therapeutic Market
- 8.8. Middle East & Africa Hereditary Angioedema Therapeutic Market
 - 8.8.1. Saudi Arabia Hereditary Angioedema Therapeutic Market
 - 8.8.2. South Africa Hereditary Angioedema Therapeutic Market
 - 8.8.3. Rest of Middle East & Africa Hereditary Angioedema Therapeutic Market

CHAPTER 9. COMPETITIVE INTELLIGENCE

- 9.1. Key Company SWOT Analysis
 - 9.1.1. Company
 - 9.1.2. Company
 - 9.1.3. Company
- 9.2. Top Market Strategies
- 9.3. Company Profiles
 - 9.3.1. CSL Limited
 - 9.3.1.1. Key Information
 - 9.3.1.2. Overview
 - 9.3.1.3. Financial (Subject to Data Availability)
 - 9.3.1.4. Product Summary
 - 9.3.1.5. Recent Developments
 - 9.3.2. Takeda Pharmaceutical Company Limited
 - 9.3.3. Pharming Healthcare Inc
 - 9.3.4. Sanofi S.A.
 - 9.3.5. BioCryst Pharmaceuticals Inc

- 9.3.6. Ionis Pharmaceuticals, Inc
- 9.3.7. Shire Plc
- 9.3.8. Attune Pharmaceuticals, Inc
- 9.3.9. Adverum Biotechnologies, Inc
- 9.3.10. KalVista Pharmaceuticals, Inc

CHAPTER 10. RESEARCH PROCESS

- 10.1. Research Process
 - 10.1.1. Data Mining
 - 10.1.2. Analysis
 - 10.1.3. Market Estimation
 - 10.1.4. Validation
 - 10.1.5. Publishing
- 10.2. Research Attributes
- 10.3. Research Assumption

List Of Tables

LIST OF TABLES

- TABLE 1. Global Hereditary Angioedema Therapeutic Market, report scope
- TABLE 2. Global Hereditary Angioedema Therapeutic Market estimates & forecasts by Region 2020-2030 (USD Billion)
- TABLE 3. Global Hereditary Angioedema Therapeutic Market estimates & forecasts by Drug Class 2020-2030 (USD Billion)
- TABLE 4. Global Hereditary Angioedema Therapeutic Market estimates & forecasts by Treatment Type 2020-2030 (USD Billion)
- TABLE 5. Global Hereditary Angioedema Therapeutic Market estimates & forecasts by Route of Administration 2020-2030 (USD Billion)
- TABLE 6. Global Hereditary Angioedema Therapeutic Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
- TABLE 7. Global Hereditary Angioedema Therapeutic Market by region, estimates & forecasts, 2020-2030 (USD Billion)
- TABLE 8. Global Hereditary Angioedema Therapeutic Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
- TABLE 9. Global Hereditary Angioedema Therapeutic Market by region, estimates & forecasts, 2020-2030 (USD Billion)
- TABLE 10. Global Hereditary Angioedema Therapeutic Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
- TABLE 11. Global Hereditary Angioedema Therapeutic Market by region, estimates & forecasts, 2020-2030 (USD Billion)
- TABLE 12. Global Hereditary Angioedema Therapeutic Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
- TABLE 13. Global Hereditary Angioedema Therapeutic Market by region, estimates & forecasts, 2020-2030 (USD Billion)
- TABLE 14. Global Hereditary Angioedema Therapeutic Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
- TABLE 15. Global Hereditary Angioedema Therapeutic Market by region, estimates & forecasts, 2020-2030 (USD Billion)
- TABLE 16. U.S. Hereditary Angioedema Therapeutic Market estimates & forecasts, 2020-2030 (USD Billion)
- TABLE 17. U.S. Hereditary Angioedema Therapeutic Market estimates & forecasts by segment 2020-2030 (USD Billion)
- TABLE 18. U.S. Hereditary Angioedema Therapeutic Market estimates & forecasts by segment 2020-2030 (USD Billion)

- TABLE 19. Canada Hereditary Angioedema Therapeutic Market estimates & forecasts, 2020-2030 (USD Billion)
- TABLE 20. Canada Hereditary Angioedema Therapeutic Market estimates & forecasts by segment 2020-2030 (USD Billion)
- TABLE 21. Canada Hereditary Angioedema Therapeutic Market estimates & forecasts by segment 2020-2030 (USD Billion)
- TABLE 22. UK Hereditary Angioedema Therapeutic Market estimates & forecasts, 2020-2030 (USD Billion)
- TABLE 23. UK Hereditary Angioedema Therapeutic Market estimates & forecasts by segment 2020-2030 (USD Billion)
- TABLE 24. UK Hereditary Angioedema Therapeutic Market estimates & forecasts by segment 2020-2030 (USD Billion)
- TABLE 25. Germany Hereditary Angioedema Therapeutic Market estimates & forecasts, 2020-2030 (USD Billion)
- TABLE 26. Germany Hereditary Angioedema Therapeutic Market estimates & forecasts by segment 2020-2030 (USD Billion)
- TABLE 27. Germany Hereditary Angioedema Therapeutic Market estimates & forecasts by segment 2020-2030 (USD Billion)
- TABLE 28. France Hereditary Angioedema Therapeutic Market estimates & forecasts, 2020-2030 (USD Billion)
- TABLE 29. France Hereditary Angioedema Therapeutic Market estimates & forecasts by segment 2020-2030 (USD Billion)
- TABLE 30. France Hereditary Angioedema Therapeutic Market estimates & forecasts by segment 2020-2030 (USD Billion)
- TABLE 31. Italy Hereditary Angioedema Therapeutic Market estimates & forecasts, 2020-2030 (USD Billion)
- TABLE 32. Italy Hereditary Angioedema Therapeutic Market estimates & forecasts by segment 2020-2030 (USD Billion)
- TABLE 33. Italy Hereditary Angioedema Therapeutic Market estimates & forecasts by segment 2020-2030 (USD Billion)
- TABLE 34. Spain Hereditary Angioedema Therapeutic Market estimates & forecasts, 2020-2030 (USD Billion)
- TABLE 35. Spain Hereditary Angioedema Therapeutic Market estimates & forecasts by segment 2020-2030 (USD Billion)
- TABLE 36. Spain Hereditary Angioedema Therapeutic Market estimates & forecasts by segment 2020-2030 (USD Billion)
- TABLE 37. RoE Hereditary Angioedema Therapeutic Market estimates & forecasts, 2020-2030 (USD Billion)
- TABLE 38. RoE Hereditary Angioedema Therapeutic Market estimates & forecasts by

segment 2020-2030 (USD Billion)

TABLE 39. RoE Hereditary Angioedema Therapeutic Market estimates & forecasts by segment 2020-2030 (USD Billion)

TABLE 40. China Hereditary Angioedema Therapeutic Market estimates & forecasts, 2020-2030 (USD Billion)

TABLE 41. China Hereditary Angioedema Therapeutic Market estimates & forecasts by segment 2020-2030 (USD Billion)

TABLE 42. China Hereditary Angioedema Therapeutic Market estimates & forecasts by segment 2020-2030 (USD Billion)

TABLE 43. India Hereditary Angioedema Therapeutic Market estimates & forecasts, 2020-2030 (USD Billion)

TABLE 44. India Hereditary Angioedema Therapeutic Market estimates & forecasts by segment 2020-2030 (USD Billion)

TABLE 45. India Hereditary Angioedema Therapeutic Market estimates & forecasts by segment 2020-2030 (USD Billion)

TABLE 46. Japan Hereditary Angioedema Therapeutic Market estimates & forecasts, 2020-2030 (USD Billion)

TABLE 47. Japan Hereditary Angioedema Therapeutic Market estimates & forecasts by segment 2020-2030 (USD Billion)

TABLE 48. Japan Hereditary Angioedema Therapeutic Market estimates & forecasts by segment 2020-2030 (USD Billion)

TABLE 49. South Korea Hereditary Angioedema Therapeutic Market estimates & forecasts, 2020-2030 (USD Billion)

TABLE 50. South Korea Hereditary Angioedema Therapeutic Market estimates & forecasts by segment 2020-2030 (USD Billion)

TABLE 51. South Korea Hereditary Angioedema Therapeutic Market estimates & forecasts by segment 2020-2030 (USD Billion)

TABLE 52. Australia Hereditary Angioedema Therapeutic Market estimates & forecasts, 2020-2030 (USD Billion)

TABLE 53. Australia Hereditary Angioedema Therapeutic Market estimates & forecasts by segment 2020-2030 (USD Billion)

TABLE 54. Australia Hereditary Angioedema Therapeutic Market estimates & forecasts by segment 2020-2030 (USD Billion)

TABLE 55. RoAPAC Hereditary Angioedema Therapeutic Market estimates & forecasts, 2020-2030 (USD Billion)

TABLE 56. RoAPAC Hereditary Angioedema Therapeutic Market estimates & forecasts by segment 2020-2030 (USD Billion)

TABLE 57. RoAPAC Hereditary Angioedema Therapeutic Market estimates & forecasts by segment 2020-2030 (USD Billion)

TABLE 58. Brazil Hereditary Angioedema Therapeutic Market estimates & forecasts, 2020-2030 (USD Billion)

TABLE 59. Brazil Hereditary Angioedema Therapeutic Market estimates & forecasts by segment 2020-2030 (USD Billion)

TABLE 60. Brazil Hereditary Angioedema Therapeutic Market estimates & forecasts by segment 2020-2030 (USD Billion)

TABLE 61. Mexico Hereditary Angioedema Therapeutic Market estimates & forecasts, 2020-2030 (USD Billion)

TABLE 62. Mexico Hereditary Angioedema Therapeutic Market estimates & forecasts by segment 2020-2030 (USD Billion)

TABLE 63. Mexico Hereditary Angioedema Therapeutic Market estimates & forecasts by segment 2020-2030 (USD Billion)

TABLE 64. RoLA Hereditary Angioedema Therapeutic Market estimates & forecasts, 2020-2030 (USD Billion)

TABLE 65. RoLA Hereditary Angioedema Therapeutic Market estimates & forecasts by segment 2020-2030 (USD Billion)

TABLE 66. RoLA Hereditary Angioedema Therapeutic Market estimates & forecasts by segment 2020-2030 (USD Billion)

TABLE 67. Saudi Arabia Hereditary Angioedema Therapeutic Market estimates & forecasts, 2020-2030 (USD Billion)

TABLE 68. South Africa Hereditary Angioedema Therapeutic Market estimates & forecasts by segment 2020-2030 (USD Billion)

TABLE 69. RoMEA Hereditary Angioedema Therapeutic Market estimates & forecasts by segment 2020-2030 (USD Billion)

TABLE 70. List of secondary sources, used in the study of global Hereditary Angioedema Therapeutic Market

TABLE 71. List of primary sources, used in the study of global Hereditary Angioedema Therapeutic Market

TABLE 72. Years considered for the study

TABLE 73. Exchange rates considered

List of tables and figures and dummy in nature, final lists may vary in the final deliverable

List Of Figures

LIST OF FIGURES

FIG 1. Global Hereditary Angioedema Therapeutic Market, research methodology

FIG 2. Global Hereditary Angioedema Therapeutic Market, Market estimation techniques

FIG 3. Global Market size estimates & forecast methods

FIG 4. Global Hereditary Angioedema Therapeutic Market, key trends 2022

FIG 5. Global Hereditary Angioedema Therapeutic Market, growth prospects 2023-2030

FIG 6. Global Hereditary Angioedema Therapeutic Market, porters 5 force model

FIG 7. Global Hereditary Angioedema Therapeutic Market, pest analysis

FIG 8. Global Hereditary Angioedema Therapeutic Market, value chain analysis

FIG 9. Global Hereditary Angioedema Therapeutic Market by segment, 2020 & 2030 (USD Billion)

FIG 10. Global Hereditary Angioedema Therapeutic Market by segment, 2020 & 2030 (USD Billion)

FIG 11. Global Hereditary Angioedema Therapeutic Market by segment, 2020 & 2030 (USD Billion)

FIG 12. Global Hereditary Angioedema Therapeutic Market by segment, 2020 & 2030 (USD Billion)

FIG 13. Global Hereditary Angioedema Therapeutic Market by segment, 2020 & 2030 (USD Billion)

FIG 14. Global Hereditary Angioedema Therapeutic Market, regional snapshot 2020 & 2030

FIG 15. North America Hereditary Angioedema Therapeutic Market 2020 & 2030 (USD Billion)

FIG 16. Europe Hereditary Angioedema Therapeutic Market 2020 & 2030 (USD Billion)

FIG 17. Asia Pacific Hereditary Angioedema Therapeutic Market 2020 & 2030 (USD Billion)

FIG 18. Latin America Hereditary Angioedema Therapeutic Market 2020 & 2030 (USD Billion)

FIG 19. Middle East & Africa Hereditary Angioedema Therapeutic Market 2020 & 2030 (USD Billion)

List of tables and figures and dummy in nature, final lists may vary in the final deliverable

I would like to order

Product name: Global Hereditary Angioedema Therapeutic Market Size study & Forecast, by Drug Class (C1-esterase inhibitor, Bradykinin B2 receptor antagonist, Kallikrein inhibitor, Others), By Treatment Type (Prophylaxis, On-demand), By Route of Administration (Intravenous, Subcutaneous, Oral) and Regional Analysis, 2023-2030

Product link: <https://marketpublishers.com/r/G20FA72AECC2EN.html>

Price: US\$ 4,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G20FA72AECC2EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below
and fax the completed form to +44 20 7900 3970